09:51 AM EST - Akela Pharma, Inc. : announced its financial results for the three months and year ended March 31, 2011. Total consolidated revenues for the quarter were $4.2 million, including $3.0 million of contract services, as compared to $2.6 million, including $1.6 million of contract services, for the same period during the previous year. Consolidated net income for the three months ended March 31, 2011 were $0.99 million, $0.03 per share, versus a loss of $0.32 million, ($0.01) per share, for the same periods in 2010. Akela Pharma, Inc.
shares T.AKL are trading even at $0.17.
